Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 15/20 | 0.58 |
| ▸ | MAOA | P21397 | 5/20 | 0.58 |
| ▸ | GRM5 | P41594 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.56 |
| ▸ | RELA | Q04206 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA5A | P35218 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4707088 | 0.82 | MAOB (0.58) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL3452161 | 0.79 | MAOB (0.52) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL12470264 | 0.76 | MAOB (0.70) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL19809528 | 0.74 | MAOB (0.56) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL21213879 | 0.74 | MAOB (1.00) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL7033212 | 0.74 | ITGB2 (0.40) | NPC1NFKB1RAB9ANFKB2RELA | |
| SCHEMBL949460 | 0.72 | MAOB (0.51) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL13213562 | 0.72 | MAOB (0.54) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL2326572 | 0.72 | MAOB (1.00) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL29889798 | 0.72 | MAOB (1.00) | MAOBMAOAGRM5NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2001844-A2 | BICYCLIC CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS | Amgen, Inc (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20070244155-A1 | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders | AMGEN INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244155-A1 | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders | AMGEN INC. (US) | 2007-10-18 | — | — | US | disclosed |
| WO-2007106469-A2 | BICYCLIC CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244155-A1 | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders | GOT2, PC, GOT1 | MAOB 603/4885MAOA 737/4885GRM5 1163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.